1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: GLP-1 Expectations Dashed

Pfizer’s Foray Into Obesity Slims Down As Tolerability Becomes The New Battleground

 
• By Andy Smith

If oral GLP-1 agonists are going to be successful in a wider weight loss indication, lower efficacy may be the trade-off for better tolerability in this bigger and more healthy population.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The title of a note on Pfizer Inc.* by the analysts at J.P. Morgan in late November included the question “Where Is The Bottom?” – referring to its stock price. At that time, Pfizer’s stock price had fallen in the year to the end of November by over 40%. This compared with an 11-month gain of just over 2% for the NYSE Arca Pharmaceutical Index (DRG). Among the list of Pfizer’s key pipeline assets highlighted in the note was the oral GLP-1 agonist danuglipron where the J.P. Morgan analysts saw “a favorable risk/reward into ph2 data” as Pfizer attempted to encroach on Novo Nordisk A/Ss and Eli Lilly and Company’s market for GLP-1 agonists in diabetes and obesity.

Expectations for the Phase II study of danuglipron had been running high long before the licensing of another oral GLP-1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

More from Business

Finance Watch: Is Six The Magic Number? May Sees Half Dozen VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.